Claims

1. A method for immunizing a patient against influenza virus comprising the step of administering an immunogenic composition to the patient, wherein(a) the patient is immunologically naive to influenza virus;(b) the immunogenic composition comprises an influenza virus antigen; and(c) the immunogenic composition is delivered to the patient's Langerhans cells.

2. The method of claim 1, wherein the patient is a child aged between 0 and 18 months.

3. The method of claim 1, wherein the immunogenic composition is delivered to the patient's Langerhans cells by intradermal injection, transdermal injection or topical administration.

4. The method of claim 1, wherein the immunogenic composition further comprises an adjuvant.

5. The method of claim 1, wherein the immunogenic composition comprises 15 μg of HA per strain of influenza virus.

6. The method of claim 1, wherein the immunogenic composition comprises between 0.1 and 8 μg of HA per strain of influenza virus.

7. The method of claim 1, wherein the immunogenic composition has a volume of between 0.05 and 0.5 ml.

8. A method for immunizing a patient against an influenza virus comprising the step of administering an immunogenic composition to the patient, wherein(a) the patient is immunologically naive to the influenza virus genus;(b) the immunogenic composition comprises an influenza virus antigen; and(c) the immunogenic composition is delivered to the patient's Langerhans.

9. The method of claim 8, wherein the patient is immunologically naive to the influenza virus subtype.

10. The use of an influenza virus antigen in the manufacture of a medicament for immunizing a patient against influenza virus, wherein:(a) the delivery device includes an immunogenic composition;(b) the immunogenic composition comprises an influenza virus antigen; and(c) the delivery device is adapted to deliver the immunogenic composition to Langerhans cells.